<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02801812</url>
  </required_header>
  <id_info>
    <org_study_id>SG_MC/RD4</org_study_id>
    <nct_id>NCT02801812</nct_id>
  </id_info>
  <brief_title>Observational Multicenter Case-control Study to Assess Nailfold Capillary Abnormalities in Systemic Lupus Erythematosus</brief_title>
  <official_title>An Observational Multicenter International Case-control Study for the Assessment of Nailfold Capillary Abnormalities in Patients With Systemic Lupus Erythematosus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ASST Gaetano Pini-CTO</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>EULAR study group on microcirculation in rheumatic diseases</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>ASST Gaetano Pini-CTO</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the role of nailfold capillaroscopy in the&#xD;
      assessment of patients with Systemic Lupus Erythematosus (SLE).&#xD;
&#xD;
      Primary endpoint:&#xD;
&#xD;
      - To compare the frequency of major capillaroscopic abnormalities in patients with SLE and&#xD;
      healthy controls.&#xD;
&#xD;
      Secondary endpoints:&#xD;
&#xD;
        -  To compare the frequency of major capillaroscopic abnormalities in patients with active&#xD;
           and non-active SLE / active SLE and healthy controls / non-active SLE and healthy&#xD;
           controls.&#xD;
&#xD;
        -  To study the association of different capillaroscopic parameters and the status of&#xD;
           subjects (SLE / active SLE / non-active SLE / healthy controls).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background and rationale:&#xD;
&#xD;
      Nailfold capillaroscopy (NC) is a diagnostic investigation used in the routine clinical&#xD;
      setting for the differential diagnosis of connective tissue diseases, such as Systemic Lupus&#xD;
      Erythematosus (SLE). Among SLE clinical manifestations, vascular involvement is a common&#xD;
      feature and a variable prevalence of NC abnormalities has been reported in SLE: typical NC&#xD;
      changes, as well as non-specific variations as observed in healthy subjects.&#xD;
&#xD;
      At this very moment literature is interspersed with different descriptions of capillaroscopic&#xD;
      features in SLE, and it has not been clearly defined the role of NC in SLE patients. It has&#xD;
      been suggested that the presence of major capillary abnormalities may reflect the&#xD;
      microvascular systemic involvement in SLE, and it may correlate to the disease activity.&#xD;
&#xD;
      Against this background, the EULAR study group on microcirculation in rheumatic diseases&#xD;
      planned an international multicenter study.&#xD;
&#xD;
      Objective:&#xD;
&#xD;
      To investigate the role of NC abnormalities in the assessment of SLE patients.&#xD;
&#xD;
      Endpoints:&#xD;
&#xD;
      Primary endpoint:&#xD;
&#xD;
      -To compare the frequency of major capillary abnormalities in patients with SLE and healthy&#xD;
      controls.&#xD;
&#xD;
      Secondary endpoints:&#xD;
&#xD;
        -  To compare the frequency of major capillary abnormalities in patients with active and&#xD;
           non-active SLE / active SLE and healthy controls / non-active SLE and healthy controls.&#xD;
&#xD;
        -  To study the association of different capillary parameters and the status of subjects&#xD;
           (SLE / active SLE / non-active SLE / healthy controls).&#xD;
&#xD;
      No. of subjects:&#xD;
&#xD;
      Total entered: 364 ; Cases (SLE): 182 ; Controls: 182.&#xD;
&#xD;
      Variables&#xD;
&#xD;
      NC assessment: presence of major capillary abnormalities; NC parameters/mm: number of&#xD;
      capillaries, presence of hairpin, tortuous, crossed, bushy, ramified, enlarged, giant&#xD;
      capillaries, microhemorrhages, architecture disorganization, visibility of the subpapillary&#xD;
      venular plexus; presence of scleroderma patterns, normal patterns.&#xD;
&#xD;
      Clinical assessment: all subjects: date of birth, gender, race. SLE: age at disease onset,&#xD;
      disease activity (SLEDAI-2000) and damage index (SLICC-DI), presence of antinuclear&#xD;
      antibodies, anti-dsDNA, anti-Extractable Nuclear Antigen antibodies, lupus anticoagulant,&#xD;
      anticardiolipin/beta2glycoprotein I antibodies, Raynaud's phenomenon, Hypertension, active&#xD;
      smoke, diabetes mellitus, ongoing and cumulative dose steroid treatment, ongoing&#xD;
      immunomodulatory/suppressive treatment.&#xD;
&#xD;
      Statistical methods For the primary endpoint and similar secondary endpoints, McNemar test&#xD;
      (matching design) and a conditional odds ratio (OR). For other secondary endpoints, the&#xD;
      Fisher's exact test and an OR, and a conditional logistic regression model (matching design)&#xD;
      and non-conditional regression model and OR as appropriate.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Enrolling by invitation</last_known_status>
  <start_date>January 2016</start_date>
  <completion_date type="Anticipated">June 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>major capillary abnormalities</measure>
    <time_frame>Day 1</time_frame>
    <description>To compare the frequency of major capillary abnormalities in patients with SLE and healthy controls.</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">364</enrollment>
  <condition>Systemic Lupus Erythematosus</condition>
  <arm_group>
    <arm_group_label>Systemic Lupus Erythematosus</arm_group_label>
    <description>patients ≥18 years diagnosed SLE upon classification according to 2012 SLICC criteria and disease onset ≥16 years.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy controls</arm_group_label>
    <description>subjects ≥18 years fulfilling the definition proposed in the protocol.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>nailfold capillaroscopy</intervention_name>
    <description>Detection by nailfold capillaroscopy of capillary abnormalities in patients with Systemic Lupus Erythematosus and comparison with healthy controls at enrolment</description>
    <arm_group_label>Healthy controls</arm_group_label>
    <arm_group_label>Systemic Lupus Erythematosus</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        patients ≥18 years diagnosed with SLE upon classification according to 2012 SLICC criteria&#xD;
        and disease onset ≥16 years.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  At time of enrollment all subjects must be 18 years or older and give written consent.&#xD;
&#xD;
          -  Patients with SLE must fulfill the 2012 SLICC classification criteria.&#xD;
&#xD;
          -  SLE onset must be over 16 years of age.&#xD;
&#xD;
          -  Patients with SLE and secondary anti-phospholipid syndrome will be also enrolled.&#xD;
&#xD;
          -  Healthy controls will be selected according to the definition proposed in the protocol&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subject refuses to sign and/or he/she is not able to understand the patient informed&#xD;
             consent.&#xD;
&#xD;
          -  Subjects with periungual traumatic lesions that may create artifacts (i.e. recent&#xD;
             manicure, onychophagia, or gardening).&#xD;
&#xD;
          -  SLE overlapping with other rheumatic diseases such as Systemic Sclerosis, Rheumatoid&#xD;
             Arthritis, Mixed Connective Tissue Disease, Sjögren's Syndrome, Dermatomyositis,&#xD;
             Polymyositis&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Francesca Ingegnoli, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>ASST Gaetano Pini-CTO</affiliation>
  </overall_official>
  <reference>
    <citation>Petri M, Orbai AM, Alarcón GS, Gordon C, Merrill JT, Fortin PR, Bruce IN, Isenberg D, Wallace DJ, Nived O, Sturfelt G, Ramsey-Goldman R, Bae SC, Hanly JG, Sánchez-Guerrero J, Clarke A, Aranow C, Manzi S, Urowitz M, Gladman D, Kalunian K, Costner M, Werth VP, Zoma A, Bernatsky S, Ruiz-Irastorza G, Khamashta MA, Jacobsen S, Buyon JP, Maddison P, Dooley MA, van Vollenhoven RF, Ginzler E, Stoll T, Peschken C, Jorizzo JL, Callen JP, Lim SS, Fessler BJ, Inanc M, Kamen DL, Rahman A, Steinsson K, Franks AG Jr, Sigler L, Hameed S, Fang H, Pham N, Brey R, Weisman MH, McGwin G Jr, Magder LS. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum. 2012 Aug;64(8):2677-86. doi: 10.1002/art.34473.</citation>
    <PMID>22553077</PMID>
  </reference>
  <reference>
    <citation>Gladman DD, Ibañez D, Urowitz MB. Systemic lupus erythematosus disease activity index 2000. J Rheumatol. 2002 Feb;29(2):288-91.</citation>
    <PMID>11838846</PMID>
  </reference>
  <verification_date>August 2017</verification_date>
  <study_first_submitted>June 13, 2016</study_first_submitted>
  <study_first_submitted_qc>June 15, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 16, 2016</study_first_posted>
  <last_update_submitted>August 8, 2017</last_update_submitted>
  <last_update_submitted_qc>August 8, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 9, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>ASST Gaetano Pini-CTO</investigator_affiliation>
    <investigator_full_name>Ingegnoli Francesca</investigator_full_name>
    <investigator_title>MD, PhD</investigator_title>
  </responsible_party>
  <keyword>Nailfold Capillaroscopy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lupus Erythematosus, Systemic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

